GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cumberland Pharmaceuticals Inc (NAS:CPIX) » Definitions » FCF Yield %

Cumberland Pharmaceuticals (Cumberland Pharmaceuticals) FCF Yield % : 23.41 (As of Apr. 30, 2024)


View and export this data going back to 2009. Start your Free Trial

What is Cumberland Pharmaceuticals FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Cumberland Pharmaceuticals's Trailing 12-Month Free Cash Flow is $5.64 Mil, and Market Cap is $24.10 Mil. Therefore, Cumberland Pharmaceuticals's FCF Yield % for today is 23.41%.

The historical rank and industry rank for Cumberland Pharmaceuticals's FCF Yield % or its related term are showing as below:

CPIX' s FCF Yield % Range Over the Past 10 Years
Min: -8.9   Med: 3.08   Max: 37.2
Current: 23.41


During the past 13 years, the highest FCF Yield % of Cumberland Pharmaceuticals was 37.20%. The lowest was -8.90%. And the median was 3.08%.

CPIX's FCF Yield % is ranked better than
97.05% of 1083 companies
in the Drug Manufacturers industry
Industry Median: -0.61 vs CPIX: 23.41

Cumberland Pharmaceuticals's FCF Margin % for the quarter that ended in Dec. 2023 was 10.19%.


Cumberland Pharmaceuticals FCF Yield % Historical Data

The historical data trend for Cumberland Pharmaceuticals's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cumberland Pharmaceuticals FCF Yield % Chart

Cumberland Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
FCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.59 7.47 8.70 19.73 22.29

Cumberland Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 24.71 -22.63 97.56 17.00 15.07

Competitive Comparison of Cumberland Pharmaceuticals's FCF Yield %

For the Drug Manufacturers - Specialty & Generic subindustry, Cumberland Pharmaceuticals's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cumberland Pharmaceuticals's FCF Yield % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cumberland Pharmaceuticals's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Cumberland Pharmaceuticals's FCF Yield % falls into.



Cumberland Pharmaceuticals FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Cumberland Pharmaceuticals's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=5.641 / 25.30202906
=22.29%

Cumberland Pharmaceuticals's annualized FCF Yield % for the quarter that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=0.953 * 4 / 25.30202906
=15.07%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cumberland Pharmaceuticals FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Cumberland Pharmaceuticals FCF Yield % Related Terms

Thank you for viewing the detailed overview of Cumberland Pharmaceuticals's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cumberland Pharmaceuticals (Cumberland Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
1600 West End Avenue, Suite 1300, Nashville, TN, USA, 37203
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The company's primary target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, RediTrex, Sancuso, Vaprisol and Vibativ.
Executives
Todd M. Anthony officer: Vice Pres Organizational Dev 1600 WEST END AVENUE, SUITE 1300, NASHVILLE TN 37203
Chris T. Bitterman officer: Vice Pres Sales & Marketing 1600 WEST END AVENUE, SUITE 1300, NASHVILLE TN 37203
Joseph C Galante director 111 TENTH AVENUE, SUITE 200, NASHVILLE TN 37203
James Jones director 2525 WEST END AVE., SUITE 950, NASHVILLE TN 37203
Kenneth Krogulski director 2525 WEST END AVENUE, SUITE 950, NASHVILLE TN 37203
Caroline Young director 2525 WEST END AVENUE, SUITE 950, NASHVILLE TN 37203
Brown Martin S Jr director 850 DIXIE HIGHWAY, LOUISVILLE KY 40210
A J Kazimi director, 10 percent owner, officer: Chairman and CEO 1207 17TH AVENUE SUITE 103, NASHVILLE TN 37212
Martin E Cearnal director 31 UPPER MOUNTAIN AVENUE, APARTMENT 2, MONTCLAIR NJ 07042
John M. Hamm officer: Chief Financial Officer 2525 WEST END AVENUE, SUITE 950, NASHVILLE TN 37203
Gordon R Bernard officer: Senior Vice President 2525 WEST END AVENUE, SUITE 950, NASHVILLE TN 37203
Joey A Jacobs director 830 CRESCENT CENTER DRIVE, SUITE 610, FRANKLIN TN 37067
Michael Bonner officer: Chief Financial Officer 2525 WEST END AVENUE, SUITE 950, NASHVILLE TN 37203
Jonathan Griggs director 2525 WEST END AVENUE, SUITE 950, NASHVILLE TN 37203
Thomas R Lawrence director 1880 ELLINGTON WAY, AUBURN AL 36830